Open AccessThe role of IL-36γ/IL-1F9 in developing erythroderma in patients with psoriasis
Author(s) -
D V Zaslavskiy,
Заславский Денис Владимирович,
И. Н. Чупров,
Чупров Игорь Николаевич,
А А Сыдиков,
Сыдиков Акмал Абдикахарович,
K U Ibragimov,
Ибрагимов Кудратилла Уткурович,
P. Wolkenstein,
Волькенштейн Пьер,
С. В. Скрек,
Скрек Сергей Владиславович,
Ruslan A. Nasyrov,
Насыров Руслан Абдуллаевич
Publication year - 2015
Publication title -
kazanskij medicinskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2587-9359
pISSN - 0368-4814
DOI - 10.17750/kmj2015-080
Subject(s) - erythroderma , psoriasis , medicine , dermatology , disease , atopic dermatitis , exfoliative dermatitis , immunology , pathology
Erythroderma is the term used for naming any inflammatory skin disease affecting over 90% of cutaneous surface. Numerous etiologic factors may background erythroderma; however, this condition is most often associated with such underlying diseases as eczema, drug hypersensitivity syndrome, cutaneous epidermotropic lymphoma, photosensitization. Being the most severe clinical form of psoriasis, psoriatic erythroderma may be a life hazard in patients with psoriasis, requiring admission and systemic treatment. The paper reviews modern data on psoriasis and psoriatic erythroderma pathogenesis. The biological role of IL-36γ/IL-1F9 - novel specific marker of psoriasis - is described in detail. Data of researches of this marker in different forms of inflammatory skin disease are discussed. Unlike other earlier described markers of psoriasis, for example, S100 A7, A8, A9 proteins, IL-36γ was highly specific to psoriasis, and rarely found at other inflammatory skin diseases (atopic dermatitis, contact dermatitis). The role of IL-36γ in diagnosing erythroderma in patients with psoriasis is described. The most specific and promising marker for distinguishing psoriatic erythroderma from other forms of erythroderma, IL-36γ can be detected at early stages of the disease, allowing to administer early causative treatment, improving treatment effect and preventing complications.